Abstract
Health care institutions, physicians, and patients can—and should—be more involved in evaluating the role of new therapies such as ramucirumab in metastatic colorectal cancer based on their value. This is especially true in the case of a treatment that adds no additional benefit in terms of efficacy or toxicity compared with the current standard of care and has a higher cost.
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / economics
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / economics*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives
-
Clinical Trials, Phase III as Topic
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / economics*
-
Colorectal Neoplasms / pathology
-
Cost-Benefit Analysis
-
Drug Costs
-
Fluorouracil / administration & dosage
-
Humans
-
Leucovorin / administration & dosage
-
Neoplasm Metastasis
-
Ramucirumab
-
Randomized Controlled Trials as Topic
-
United States
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Leucovorin
-
Fluorouracil
-
Camptothecin